Bayer pays $310M to buy into BridgeBio heart drug

Bayer pays $310M to buy into BridgeBio heart drug

Submitted by admin on March 4, 2024 - 11:52am
Source: 
BioPharma Dive
News Tags: 
BridgeBio
Bayer
acoramidis
Pfizer
Vyndamax
transthyretin amyloidosis cardiomyopathy
Headline: 
Bayer pays $310M to buy into BridgeBio heart drug
snippet: 

The deal gives the German pharma partial rights to acoramidis, a treatment that could soon become a marketed rival of a fast-selling Pfizer medicine.

Do Not Allow Advertisers to Use My Personal information